wve-n531
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2021 (NCT04906460)
Timeline
Indications
Studied for
Mechanism of action
- Dystrophin pre-mRNAANTISENSE INHIBITOR
Dystrophin pre-mRNA antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07209332 | Phase 2 | Nov 30, 2025 | Wave Life Sciences |
| NCT04906460 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2021 | Wave Life Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wave Life Sciences | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1